| |
 |
|
Development and sales of competitive new products to create profit and contribute to public health
|
|
|
|
 |
 |
 |
Continued drive to in-license new products and specific remedies |
|
Development of competitive product through R&D |
|
Increase productivity through outsourcing or forming consortium with domestic and
international companies |
|
|
|
|
|
 |
|
Continued drive to in-license new products and specific remedies |
-
-
-
|
Priority Indications : Cardio-Vascular, Respiratory, Endocrinology, CNS, Ob/Gyn, Gastro-Intestinal, Dermatology, and Cancer
Establishment of new international partners and strengthening partnership with existing partners
Decrease the time required for in-licensing and new product sales
|
|
Development of competitive product through R&D |
-
-
-
-
|
Development of new QOL (Quality of Life) products, hypertensives, diabetes, Alzheimer’s Disease, Depression, Obesity, Hair loss, etc.
Development of patented products
Development of 1 generic products
Development of combination/new formulation products/formulation, increased/new indication, improved posology, improved safety, better absorption, etc.
|
|
Increase productivity through outsourcing or forming consortium with domestic and international companies |
-
-
-
|
Establish plans for new clinical and bio-equivalency tests
Establish partnership with academia and research facilities
Organize new production/research/development/marketing/sales outsourcing and consortiums
|
|
|
|
